Viewing Study NCT00050999



Ignite Creation Date: 2024-05-05 @ 11:28 AM
Last Modification Date: 2024-10-26 @ 9:08 AM
Study NCT ID: NCT00050999
Status: COMPLETED
Last Update Posted: 2008-03-05
First Post: 2002-12-31

Brief Title: Study of ONTAK Denileukin Diftitox in Cutaneous T-Cell Lymphoma CTCL Patients
Sponsor: Eisai Inc
Organization: Eisai Inc

Study Overview

Official Title: A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 9 and 18 McgkgDay in Cutaneous T-Cell Lymphoma CTCL Patients With Stage Ia-III Disease Who Following Less Than or Equal to 3 Previous Therapies Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25
Status: COMPLETED
Status Verified Date: 2008-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to compare the effectiveness of two dose levels of ONTAK denileukin diftitox in treating patients who have recurrent or persistent cutaneous T-cell lymphoma
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None